New study finds students with weight issues purchase weight-loss products found in e-mail ads
BROOKLYN, N.Y. According to a study published in the January issue of the Southern Medical Journal, 41% of college students with weight problems opened and read spam e-mail advertising “lose weight fast” weight-loss products with 18.5% ordering these weight-loss products.
“This is of concern as there is no quality control for what is advertised in spam e-mail. These products can range from harmless to potentially dangerous,” stated Joshua Fogel, lead researcher and associate professor of the business program at the department of economics at Brooklyn College. “Some spam e-mail products even advertise and sell prescription medications without requiring proof of a valid prescription.”
In additional analyses considering the impact of a number of relevant variables, those with weight problems as compared to those without weight problems were three times more likely to open/read and also three times more likely to purchase weight-loss products from spammed e-mail.
Fogel analyzed data from a survey of 200 college students, who were asked if they had weight problems and if in the past year they received, opened/read, or purchased products from spam e-mail about weight loss topics.
Decision Resources projects same U.S., Europe patient share of ulcerative colitis biologic
WALTHAM, Mass. A new report by Decision Resources revealed that a biological therapy with a mechanism of action other than tumor necrosis factor-alpha inhibitors, used for the treatment of moderate to severe ulcerative colitis, would earn a 25% patient share in both the United States and Europe.
The report, “Ulcerative Colitis: Gastroenterologists Identify Emerging Drugs That Will Challenge the Benchmark Therapy Infliximab for Moderate to Severe UC,” finds that two emerging TNF-alpha inhibitors — Abbott/Eisai’s Humira and Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen’s Simponi — will earn Decision Resources’ proprietary clinical gold standard status for ulcerative colitis in 2013 following their approval for the indication. Both Humira and Simponi have competitive advantages over sales-leader Remicade in efficacy, delivery, and safety and tolerability.
“Although clinical trial data are limited, interviewed experts believe that both Humira and Simponi’s fully human composition will translate into incremental advantages in efficacy for maintenance of remission and maintenance of response compared to Remicade, which is a chimeric monoclonal antibody,” said Decision Resources analyst Kathryn Benton.
HHS debuts H1N1 vaccine ad during football games
WASHINGTON The Department of Health and Human Services is continuing to advocate getting the H1N1 influenza vaccine, even this late into the season, as the agency announced last week the launch of a new H1N1 flu vaccination advertisement that aired during four college football bowl games held over the New Year’s holiday.
The ad is aimed at encouraging young people and all Americans to get vaccinated against the H1N1 flu.
“Young Americans have been especially hard hit by the 2009 H1N1 flu,” stated HHS secretary Sebelius. “Sports events are important opportunities to encourage fans, athletes, young adults and all Americans to protect themselves by getting the H1N1 vaccine. We hope that college athletic teams across the country will continue to join us in the fight against the H1N1 flu by getting vaccinated and encouraging others to get vaccinated too.”
With more than 110 million doses of the 2009 H1N1 vaccine now available, “all Americans are encouraged to get vaccinated and protect themselves and their loved ones during flu season, which typically lasts from October until May,” the agency stated.
For the week ended Dec. 26, rates of reported influenza-like illnesses continued to decline, though nationwide ILI incidence is still higher than is typical for this time of the year.